These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 30587519)
1. Simultaneous CMV and Pappolla A; Midaglia L; Boix Rodríguez CP; Puig AA; Lung M; Camps IR; Castilló J; Mulero P; Vidal-Jordana A; Arrambide G; Rodriguez-Acevedo B; Sastre-Garriga J; Río J; Comabella M; Galán I; Tintoré M; Montalbán X Neurology; 2019 Feb; 92(6):296-298. PubMed ID: 30587519 [No Abstract] [Full Text] [Related]
2. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis. Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597 [TBL] [Abstract][Full Text] [Related]
3. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis. Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423 [TBL] [Abstract][Full Text] [Related]
4. Disseminated herpes zoster infection 16 months after last intake of alemtuzumab: potential long-term adverse effects. Albrecht LJ; Moelleken M; Dissemond J Clin Exp Dermatol; 2021 Apr; 46(3):550-552. PubMed ID: 32810347 [No Abstract] [Full Text] [Related]
5. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab]. Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573 [TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. Carandini T; Pietroboni AM; Sacchi L; De Riz MA; Pozzato M; Arighi A; Fumagalli GG; Martinelli Boneschi F; Galimberti D; Scarpini E Mult Scler; 2020 Sep; 26(10):1268-1269. PubMed ID: 32463329 [No Abstract] [Full Text] [Related]
7. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848 [TBL] [Abstract][Full Text] [Related]
8. Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab. Eichau S; López Ruiz R; Castón Osorio JJ; Ramírez E; Domínguez-Mayoral A; Izquierdo G Neurologia (Engl Ed); 2020; 35(6):440-443. PubMed ID: 29907474 [No Abstract] [Full Text] [Related]
9. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. Brannigan J; Jones JL; Stacpoole SRL Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32522766 [No Abstract] [Full Text] [Related]
10. A case of cytomegalovirus colitis following immunosuppressive treatment for pyoderma gangrenosum. Kikuchi H; Nagamine H; Setoyama M J Dermatol; 2005 Apr; 32(4):299-302. PubMed ID: 15863855 [TBL] [Abstract][Full Text] [Related]
11. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Barton J; Hardy TA; Riminton S; Reddel SW; Barnett Y; Coles A; Barnett MH Neurology; 2017 Mar; 88(10):1004-1006. PubMed ID: 28179462 [No Abstract] [Full Text] [Related]
12. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. Walter E; Berger T; Bajer-Kornek B; Deisenhammer F J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373 [TBL] [Abstract][Full Text] [Related]
13. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis. Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912 [TBL] [Abstract][Full Text] [Related]
15. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient. Kogel AK; Gold R; Schneider R J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973 [No Abstract] [Full Text] [Related]
16. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614 [TBL] [Abstract][Full Text] [Related]
17. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Russo CV; Saccà F; Paternoster M; Buonomo AR; Gentile I; Scotto R; Brescia Morra V; Mansueto G Mult Scler; 2020 Jan; 26(1):123-126. PubMed ID: 30882274 [No Abstract] [Full Text] [Related]
18. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature. Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425 [TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report. Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116 [TBL] [Abstract][Full Text] [Related]